Manufacturing changes - such as changes in formulation or source material - can impact a product’s immunogenicity.
Alexandra Worobec, M.D.
Advertisement
Articles by Alexandra Worobec, M.D.
Neutralization of therapeutic protein products does not produce an obvious clinical deficiency syndrome for all therapeutic protein products with endogenous counterparts, because many endogenous proteins are biologically redundant.
Advertisement
Latest Updated Articles
- A Risk-Based Approach to Immunogenicity Concerns of Therapeutic Protein Products, Part 1: Considering Consequences of the Immune Response to a Protein
Published: November 1st 2004 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
